<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00435812</url>
  </required_header>
  <id_info>
    <org_study_id>DV2-HBV-10</org_study_id>
    <secondary_id>2006-006743-31</secondary_id>
    <nct_id>NCT00435812</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of HEPLISAV™ Hepatitis B Virus Vaccine Compared With Engerix-B® Vaccine</brief_title>
  <official_title>A Phase III Safety and Efficacy Study to Compare Immune Responses Following Injection With Either Two Doses of HEPLISAV™ or Three Doses of Engerix-B®</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dynavax Technologies Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dynavax Technologies Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out if a new investigational hepatitis B virus vaccine,
      HEPLISAV™, is safe and effective compared with Engerix-B® vaccine in subjects 11-55 years
      old. The primary hypothesis is that the seroprotective immune response of HEPLISAV™ is at
      least as good as that of Engerix-B®.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will evaluate the safety and efficacy of two injections of HEPLISAV™, compared
      with three injections of a commercially available hepatitis B virus (HBV) vaccine,
      Engerix-B®, in subjects 11 to 55 years old. About 2,400 subjects will be included in the
      study. Once subjects are consented, screened, and randomized to treatment, all subjects will
      receive a total of three injections over a 24-week period, with a follow-up visit at 28
      weeks. Subjects randomized to Engerix-B® will receive 3 injections of active vaccine, while
      subjects randomized to HEPLISAV™ will receive 2 injections of active vaccine plus 1 injection
      of placebo. Safety and tolerability will be evaluated by occurrence of adverse events,
      periodic laboratory tests, vital signs, and local/systemic reactogenicity.

      Comparison: Subjects will receive treatment with either HEPLISAV™ or the comparator vaccine,
      Engerix-B®.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Subjects With Seroprotective Immune Response</measure>
    <time_frame>Week 12 for HEPLISAV and Week 28 for Engerix-B</time_frame>
    <description>Percentage of subjects who have a seroprotective immune response (anti-HBsAg ≥ 10 milli-international unit (mIU)/mL) after the final active injection in each treatment group (Week 12 for HEPLISAV™ and Week 28 for Engerix-B®)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Local and Systemic Reactions to Injections</measure>
    <time_frame>Within 7 days post-injection for Post Injection Reactions</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2428</enrollment>
  <condition>Hepatitis B</condition>
  <arm_group>
    <arm_group_label>HEPLISAV and/or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5 mL HEPLISAV (20 mcg HBsAg and 3000 mcg 1018)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Engerix-B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1.0 mL Engerix-B</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HEPLISAV and/or Placebo</intervention_name>
    <description>Intramuscular (IM) injections on Week 0, Week 4; placebo (saline) injection at Week 24</description>
    <arm_group_label>HEPLISAV and/or Placebo</arm_group_label>
    <other_name>HEPLISAV</other_name>
    <other_name>Hepatitis B vaccine (recombinant), adjuvanted</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Engerix-B</intervention_name>
    <description>Intramuscular (IM) injections on Week 0, Week 4, and Week 24</description>
    <arm_group_label>Engerix-B</arm_group_label>
    <other_name>Hepatitis B vaccine (recombinant)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Willing and able to give written informed consent

          -  Is serum negative for HBV antibodies

        Exclusion Criteria:

          -  Women who are pregnant or breastfeeding

          -  Any previous HBV infection

          -  Previous vaccination with any HBV vaccine (1 or more doses)

          -  Any autoimmune disease

          -  Received any blood products or antibodies within 3 months prior to study entry

          -  Ever received an injection with DNA plasmids or oligonucleotides

          -  Received any vaccines within 4 weeks prior to study entry

          -  Received any other investigational medicinal agent within 4 weeks prior to study entry
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>11 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>J. Tyler Martin, Sr, MD</last_name>
    <role>Study Director</role>
    <affiliation>Dynavax Technologies Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mount Pearl</city>
        <state>Newfoundland and Labrador</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sarnia</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charlottetown</city>
        <state>Prince Edward Island</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Québec</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Magdeburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ulm</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.dynavax.com</url>
    <description>Dynavax Webpage</description>
  </link>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 13, 2007</study_first_submitted>
  <study_first_submitted_qc>February 14, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2007</study_first_posted>
  <results_first_submitted>December 8, 2017</results_first_submitted>
  <results_first_submitted_qc>January 15, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">February 13, 2018</results_first_posted>
  <disposition_first_submitted>June 16, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>June 16, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">June 19, 2014</disposition_first_posted>
  <last_update_submitted>January 15, 2018</last_update_submitted>
  <last_update_submitted_qc>January 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HBV vaccine</keyword>
  <keyword>Hepatitis B vaccine</keyword>
  <keyword>Hepatitis B</keyword>
  <keyword>Hepatitis</keyword>
  <keyword>HBV</keyword>
  <keyword>Immunostimulatory sequence (ISS)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>HEPLISAV and/or Placebo</title>
          <description>0.5 mL HEPLISAV (20 mcg HBsAg and 3000 mcg 1018)
HEPLISAV and/or Placebo: Intramuscular (IM) injections at Week 0 and Week 4, plus a placebo (saline) injection at Week 24</description>
        </group>
        <group group_id="P2">
          <title>Engerix-B</title>
          <description>1.0 mL Engerix-B
Engerix-B: Intramuscular (IM) injections on Week 0, Week 4, and Week 24</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1820"/>
                <participants group_id="P2" count="608"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1757"/>
                <participants group_id="P2" count="590"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="63"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety Analysis Population: All participants who received at least 1 study injection and had any post-baseline safety data.
NOTE: One (1) subject randomized to the Engerix-B group received HEPLISAV in error and was analyzed in the HEPLSAV group for the Safety Analysis Population</population>
      <group_list>
        <group group_id="B1">
          <title>HEPLISAV and/or Placebo</title>
          <description>0.5 mL HEPLISAV (20 mcg HBsAg and 3000 mcg 1018) HEPLISAV and/or Placebo: Intramuscular (IM) injections at Week 0, Week 4, plus a placebo (saline) injection at Week 24</description>
        </group>
        <group group_id="B2">
          <title>Engerix-B</title>
          <description>1.0 mL Engerix-B
Engerix-B: Intramuscular (IM) injections on Week 0, Week 4, and Week 24</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1821"/>
            <count group_id="B2" value="607"/>
            <count group_id="B3" value="2428"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>11 to 17 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥18 and ≤ 55 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1810"/>
                    <measurement group_id="B2" value="605"/>
                    <measurement group_id="B3" value="2415"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="959"/>
                    <measurement group_id="B2" value="346"/>
                    <measurement group_id="B3" value="1305"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="862"/>
                    <measurement group_id="B2" value="261"/>
                    <measurement group_id="B3" value="1123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1123"/>
                    <measurement group_id="B2" value="366"/>
                    <measurement group_id="B3" value="1489"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="698"/>
                    <measurement group_id="B2" value="241"/>
                    <measurement group_id="B3" value="939"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects With Seroprotective Immune Response</title>
        <description>Percentage of subjects who have a seroprotective immune response (anti-HBsAg ≥ 10 milli-international unit (mIU)/mL) after the final active injection in each treatment group (Week 12 for HEPLISAV™ and Week 28 for Engerix-B®)</description>
        <time_frame>Week 12 for HEPLISAV and Week 28 for Engerix-B</time_frame>
        <population>Per Protocol Population: Subjects who met eligibility criteria, did not violate the protocol in a substantial manner, received all protocol-specified study injections, had their primary serology and all injections within the specified day ranges, and had serology at their primary endpoint (Week 12 for HEPLISAV group and Week 28 for Engerix-B group)</population>
        <group_list>
          <group group_id="O1">
            <title>HEPLISAV and/or Placebo</title>
            <description>0.5 mL HEPLISAV (20 mcg HBsAg and 3000 mcg 1018)
HEPLISAV and/or Placebo: Intramuscular (IM) injections at Week 0, Week 4, plus a placebo (saline) injection at Week 24</description>
          </group>
          <group group_id="O2">
            <title>Engerix-B</title>
            <description>1.0 mL Engerix-B
Engerix-B: Intramuscular (IM) injections on Week 0, Week 4, and Week 24</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Seroprotective Immune Response</title>
          <description>Percentage of subjects who have a seroprotective immune response (anti-HBsAg ≥ 10 milli-international unit (mIU)/mL) after the final active injection in each treatment group (Week 12 for HEPLISAV™ and Week 28 for Engerix-B®)</description>
          <population>Per Protocol Population: Subjects who met eligibility criteria, did not violate the protocol in a substantial manner, received all protocol-specified study injections, had their primary serology and all injections within the specified day ranges, and had serology at their primary endpoint (Week 12 for HEPLISAV group and Week 28 for Engerix-B group)</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1520"/>
                <count group_id="O2" value="523"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.1"/>
                    <measurement group_id="O2" value="81.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Local and Systemic Reactions to Injections</title>
        <time_frame>Within 7 days post-injection for Post Injection Reactions</time_frame>
        <population>Safety Analysis Population: All participants who received at least 1 study injection and had any post-baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>HEPLISAV and/or Placebo</title>
            <description>0.5 mL HEPLISAV (20 mcg HBsAg and 3000 mcg 1018)
HEPLISAV and/or Placebo: Intramuscular (IM) injections at Week 0, Week 4, plus a placebo (saline) injection at Week 24</description>
          </group>
          <group group_id="O2">
            <title>Engerix-B</title>
            <description>1.0 mL Engerix-B
Engerix-B: Intramuscular (IM) injections on Week 0, Week 4, and Week 24</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Local and Systemic Reactions to Injections</title>
          <population>Safety Analysis Population: All participants who received at least 1 study injection and had any post-baseline data.</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1821"/>
                <count group_id="O2" value="607"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Local Reaction : Injection 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.4"/>
                    <measurement group_id="O2" value="34.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Local Reaction : Injection 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.8"/>
                    <measurement group_id="O2" value="24.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Local Reaction : Injection 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5"/>
                    <measurement group_id="O2" value="20.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systemic Reaction : Injection 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.1"/>
                    <measurement group_id="O2" value="29.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systemic Reaction : Injection 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.2"/>
                    <measurement group_id="O2" value="18.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systemic Reaction : Injection 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.8"/>
                    <measurement group_id="O2" value="14.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Adverse events were assessed for safety analysis population: All participants who received at least 1 study injection and had any post-baseline safety data</desc>
      <group_list>
        <group group_id="E1">
          <title>HEPLISAV and/or Placebo</title>
          <description>0.5 mL HEPLISAV (20 mcg HBsAg and 3000 mcg 1018)
HEPLISAV and/or Placebo: Intramuscular (IM) injections at Week 0, Week 4, plus a placebo (saline) injection at Week 24</description>
        </group>
        <group group_id="E2">
          <title>Engerix-B</title>
          <description>1.0 mL Engerix-B
Engerix-B: Intramuscular (IM) injections on Week 0, Week 4, and Week 24</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="1821"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="607"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1821"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="607"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1821"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="607"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1821"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="607"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1821"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="607"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1821"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="607"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1821"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="607"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1821"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="607"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anti-neutrophil cytoplasmic antibody positive vasculitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1821"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="607"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Liver abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1821"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="607"/>
              </event>
              <event>
                <sub_title>Salpingo-oophoritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1821"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="607"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1821"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="607"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1821"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="607"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1821"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="607"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1821"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="607"/>
              </event>
              <event>
                <sub_title>Jaw fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1821"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="607"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1821"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="607"/>
              </event>
              <event>
                <sub_title>Meniscus injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1821"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="607"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1821"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="607"/>
              </event>
              <event>
                <sub_title>Post procedural complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1821"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="607"/>
              </event>
              <event>
                <sub_title>Sternal fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1821"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="607"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1821"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="607"/>
              </event>
              <event>
                <sub_title>Ulna fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1821"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="607"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1821"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="607"/>
              </event>
              <event>
                <sub_title>Gouty arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1821"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="607"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1821"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="607"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1821"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="607"/>
              </event>
              <event>
                <sub_title>Breast cancer recurrent</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1821"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="607"/>
              </event>
              <event>
                <sub_title>Meningioma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1821"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="607"/>
              </event>
              <event>
                <sub_title>Papillary thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1821"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="607"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1821"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="607"/>
              </event>
              <event>
                <sub_title>Guillain-barre syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1821"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="607"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Delirium tremens</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1821"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="607"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1821"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="607"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1821"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="607"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1821"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="607"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1821"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="607"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1821"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="607"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1821"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="607"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1821"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="607"/>
              </event>
              <event>
                <sub_title>Pneumothorax spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1821"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="607"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1821"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="607"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Granulomatosis with polyangiitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1821"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="607"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="602" subjects_at_risk="1821"/>
                <counts group_id="E2" subjects_affected="191" subjects_at_risk="607"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="303" subjects_at_risk="1821"/>
                <counts group_id="E2" subjects_affected="100" subjects_at_risk="607"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="94" subjects_at_risk="1821"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="607"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="205" subjects_at_risk="1821"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="607"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Robert Janssen MD \ VP &amp; Chief Medical Officer</name_or_title>
      <organization>Dynavax Technologies, Inc.</organization>
      <phone>510-848-5100</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

